Switch to:
Also traded in: Germany

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:Q, NYSE:LH, NYSE:DGX, NAS:IDXX, OTCPK:SSMXY, NAS:DXCM, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO.B, OTCPK:SUVPF, NAS:ICLR, NYSE:CRL, NAS:CPHD, NAS:PRAH, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (50% of sales), cross lab (which includes consumables and services at 33%), and diagnostics and genomics (17%). The United States and Europe account for 36% and 30% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Ratios

vs
industry
vs
history
PE Ratio 34.06
A's PE Ratio is ranked lower than
54% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. A: 34.06 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 2.75  Med: 15.12 Max: 48.52
Current: 34.06
2.75
48.52
Forward PE Ratio 25.06
A's Forward PE Ratio is ranked lower than
51% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 25.06 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 34.06
A's PE Ratio without NRI is ranked lower than
55% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. A: 34.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 15.34 Max: 301.43
Current: 34.06
5.2
301.43
Price-to-Owner-Earnings 32.85
A's Price-to-Owner-Earnings is ranked lower than
62% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. A: 32.85 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.5  Med: 15.57 Max: 194.42
Current: 32.85
2.5
194.42
PB Ratio 4.00
A's PB Ratio is ranked lower than
56% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. A: 4.00 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.63 Max: 4.01
Current: 4
1.22
4.01
PS Ratio 4.12
A's PS Ratio is ranked lower than
56% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. A: 4.12 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.92 Max: 7.61
Current: 4.12
0.6
7.61
Price-to-Free-Cash-Flow 26.18
A's Price-to-Free-Cash-Flow is ranked lower than
55% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. A: 26.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.46  Med: 15.48 Max: 68.05
Current: 26.18
5.46
68.05
Price-to-Operating-Cash-Flow 21.82
A's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. A: 21.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.36  Med: 12.71 Max: 39.2
Current: 21.82
4.36
39.2
EV-to-EBIT 25.22
A's EV-to-EBIT is ranked lower than
61% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. A: 25.22 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.05 Max: 249.8
Current: 25.22
4.9
249.8
EV-to-EBITDA 18.65
A's EV-to-EBITDA is ranked lower than
62% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. A: 18.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 11.3 Max: 31.7
Current: 18.65
4
31.7
Shiller PE Ratio 27.63
A's Shiller PE Ratio is ranked higher than
70% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. A: 27.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.95  Med: 19.73 Max: 45.85
Current: 27.63
9.95
45.85
Current Ratio 3.34
A's Current Ratio is ranked higher than
66% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. A: 3.34 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.56 Max: 4.08
Current: 3.34
1.61
4.08
Quick Ratio 2.83
A's Quick Ratio is ranked higher than
66% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. A: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.06 Max: 3.44
Current: 2.83
1.04
3.44
Days Inventory 99.52
A's Days Inventory is ranked lower than
63% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. A: 99.52 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.82 Max: 191.04
Current: 99.52
91.25
191.04
Days Sales Outstanding 56.20
A's Days Sales Outstanding is ranked higher than
56% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. A: 56.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 52.14 Max: 84.27
Current: 56.2
47.45
84.27
Days Payable 48.74
A's Days Payable is ranked lower than
57% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. A: 48.74 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.45 Max: 79.36
Current: 48.74
43.61
79.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.90
A's Dividend Yield % is ranked lower than
57% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.82 vs. A: 0.90 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.14 Max: 1.42
Current: 0.9
0.31
1.42
Dividend Payout Ratio 0.31
A's Dividend Payout Ratio is ranked higher than
77% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. A: 0.31 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.33 Max: 0.77
Current: 0.31
0.09
0.77
Forward Dividend Yield % 0.99
A's Forward Dividend Yield % is ranked lower than
56% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.16 vs. A: 0.99 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.90
A's 5-Year Yield-on-Cost % is ranked lower than
68% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. A: 0.90 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.31  Med: 1.14 Max: 1.42
Current: 0.9
0.31
1.42
3-Year Average Share Buyback Ratio 0.90
A's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. A: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 1.05 Max: 11.4
Current: 0.9
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 279.58
A's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.90 vs. A: 279.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 11.57 Max: 1364
Current: 279.58
2.8
1364
Price-to-Tangible-Book 12.92
A's Price-to-Tangible-Book is ranked lower than
78% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. A: 12.92 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.88 Max: 13.01
Current: 12.92
1.1
13.01
Price-to-Intrinsic-Value-Projected-FCF 1.60
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. A: 1.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.19 Max: 2.86
Current: 1.6
0.61
2.86
Price-to-Median-PS-Value 2.14
A's Price-to-Median-PS-Value is ranked lower than
89% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. A: 2.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.92 Max: 3.8
Current: 2.14
0.37
3.8
Price-to-Graham-Number 4.42
A's Price-to-Graham-Number is ranked lower than
67% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. A: 4.42 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.84  Med: 1.96 Max: 9.54
Current: 4.42
0.84
9.54
Earnings Yield (Greenblatt) % 3.95
A's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. A: 3.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 7.1 Max: 20.2
Current: 3.95
0.4
20.2
Forward Rate of Return (Yacktman) % -7.31
A's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. A: -7.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 7.95 Max: 78.6
Current: -7.31
-10.2
78.6

More Statistics

Revenue (TTM) (Mil) $4,241
EPS (TTM) $ 1.56
Beta1.47
Short Percentage of Float1.64%
52-Week Range $39.11 - 54.82
Shares Outstanding (Mil)322.30

Analyst Estimate

Oct17 Oct18 Oct19
Revenue (Mil $) 4,327 4,529 4,728
EPS ($) 2.12 2.36 2.72
EPS without NRI ($) 2.12 2.36 2.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.42%
Dividends per Share ($) 0.53 0.58 0.60
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Technologies Raises Dividend 15% Dec 06 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
A High-Tech Manufacturer With Excellent Growth Prospects Nov 03 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
Agilent, Apple and Canadian Pacific Are Among Larry Robbins' New Buys Dec 22 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Larry Robbins Buys Cigna, Monsanto and Sells Out McDonald's Dec 09 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 

More From Other Websites
Cramer Remix: This stock could spike on takeover talk Mar 23 2017
Agilent Technologies Enhances Exome Sequencing for Clinical Research Mar 21 2017
Agilent Technologies Hires Samraat “Sam” Raha to Head Strategy and Corporate Development Mar 20 2017
Philip Morris International Inc. Presents at the Consumer Analyst Group of Europe (CAGE) Conference Mar 20 2017
Why Did the Healthcare Sector Fall on March 16? Mar 17 2017
Agilent (A) Up 4.8% Since Earnings Report: Can It Continue? Mar 17 2017
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 16 2017
Agilent Technologies: Koh Boon Hwee Appointed New Chairman Mar 16 2017
Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman Mar 15 2017
Agilent Technologies Announces Cash Dividend of 13.2 Cents per Share Mar 15 2017
Agilent upgraded by Morgan Stanley Mar 15 2017
AGILENT TECHNOLOGIES INC Financials Mar 14 2017
Agilent Technologies Receives 2017 Scientists’ Choice Award for Best Webinar Series Mar 14 2017
The Technician's Playbook: 11 Sector Pair Trades Mar 13 2017
Agilent Technologies Receives 2017 Scientists’ Choice Award for Best New Separation Product Mar 09 2017
AGILENT TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report Mar 08 2017
Agilent Technologies Launches New Research-Grade Triple Quadrupole LC/MS System Mar 08 2017
Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System Mar 07 2017
Agilent Technologies Should 'Ace' This Test Mar 03 2017
Agilent Technologies Introduces Postnatal Assay for Detection of Genetic Anomalies Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK